运动疗法用于预防和治疗阿尔茨海默病
1Department of Physical Education, Farhangian University, Tehran, Iran.
Frontiers in aging neuroscience
|August 21, 2023
概括
定期炼,包括有氧和力量训练,可以显著有益于阿尔茨海默病 (AD) 患者. 运动可以改善记忆力,减少炎症,通过增加神经营养因子和增强血液流动来促进大脑健康.
科学领域:
- 神经科学是一个神经科学.
- 运动生理学 运动生理学
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是痴呆和认知能力下降.
- 关键的病理特征包括粉样β (Aβ) 和陶积累,神经炎症和线粒体功能障碍.
- 目前的治疗方法有效性有限,这突显了预防和治疗策略的必要性.
研究的目的:
- 审查各种运动模式对阿尔茨海默病病理学和认知功能的多方面的益处.
- 阐明AD中运动诱导的神经保护和神经可塑性背后的分子和细胞机制.
- 探索用于AD管理的联合运动干预措施的潜力.
主要方法:
- 对研究的综合文献综述,研究了动物模型和AD的人类受试者的运动干预措施.
- 分析与粉样β,陶酸化,神经炎症,线粒体功能和神经变因子相关的分子标记物.
- 从运动干预研究中检查神经影像和认知评估数据.
主要成果:
- 中等强度和有氧运动通过调节信号通路 (例如,AKT,TrkB) 并减少AD病理学来恢复动物模型中的记忆功能.
- 运动增强了突触可塑性,并通过增加神经营养因子 (如BDNF和NGF) 来防止人类的海马体积损失.
- 有氧和高强度间歇训练可以改善大脑血液流动和血管生成,同时还可以增强线粒体形态和减少炎症.
结论:
- 运动,特别是有氧和综合训练,在缓解AD进展和改善认知和运动功能的方面表现出显著的潜力.
- 运动诱导的BDNF,NGF,VEGF和虹膜蛋白的增加有助于神经保护,神经发生和抗炎作用.
- 结合有氧,力量,平衡和认知活动的综合炼计划可能为管理阿尔茨海默病提供一种整体的方法.
相关概念视频
Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
Parkinson's Disease: Treatment
297
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
297
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Electroconvulsive Therapy
69
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
69
Parkinson's Disease: Overview
596
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
596


